Richard Maziarz, MD
Hematology & Oncology · Portland, ORNPI 1275548760
Payments from drug & device makers
Across 414 payments — averaging $4628.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$747K
- Incyte Corporation$524K
- Bristol Myers Squibb$512K
- National Marrow Donor Program$53K
- Gamida Cell Inc.$41K
- Novartis Pharma AG$12K
- plus $27K from 15 others
Across 16 payments — averaging $1511.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$24K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 102 | $747,391 |
| Incyte Corporation | 226 | $523,732 |
| Bristol Myers Squibb | 27 | $511,808 |
| National Marrow Donor Program | 16 | $53,136 |
| Gamida Cell Inc.(2 entities) | 5 | $41,301 |
| Novartis Pharma AG | 2 | $12,183 |
| E.r. Squibb & Sons, L.L.C. | 3 | $5,826 |
| Biomerieux Inc | 3 | $4,669 |
| Jazz Pharmaceuticals Inc. | 7 | $3,970 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $3,525 |
| Morphosys, US Inc. | 2 | $2,807 |
| Iovance Biotherapeutics, Inc. | 2 | $2,048 |
| Kadmon Pharmaceuticals LLC | 2 | $1,632 |
| Janssen Scientific Affairs, LLC | 4 | $1,390 |
| AstraZeneca | 3 | $283 |
| Astellas Pharma US Inc | 3 | $237 |
| Mesoblast, Inc. | 1 | $87 |
| Adaptive Biotechnologies Corporation | 1 | $64 |
| Adaptimmune LLC | 1 | $57 |
| Sobi, Inc | 1 | $42 |
| Gilead | 1 | $32 |
How this compares
$1,916,218 in reported general payments places this provider in the 85th percentile of 112 hematology & oncology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Portland
- Michael HeinrichPortland$25M
- Jay AndersenPortland$8.3M
- Elie TraerPortland$6.5M
- Jacqueline VukyPortland$5.4M
- Sandeep MashruPortland$4.6M
- Abdul Hai MansoorPortland$3.5M
- Aimee KohnPortland$3.3M
- Tibor KovacsovicsPortland$2.7M
- Emerson ChenPortland$2.5M
- Brian DrukerPortland$2.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.